Search
Login
My Portfolios Login
TradeMachine® Login
CML Research Pro Login
Get TradeMachine®
Get CML Research
Compare Products
Home
My Portfolios
CMLViz News
Breaking
Stock
Scanner
Tear Sheet
News
Profile
Stats
Stock Chart
Pivot Points
Financial Charts
Holders
Analysts
Day Trader
Back-Tester
SPX
3,950.43
+0.40
(
+0.01%
)
Dow 30
+0.01%
QQQ
-0.07%
VIX
29.76
+0.31
(
+1.05%
)
Tcr2 Therapeutics Inc
NASDAQ:TCRR 10:08:41 AM EDT
2.18
+0.02
(
+0.93%
)
Products
TCR2 Therapeutics Gets FDA Orphan Drug Designation For Cholangiocarcinoma Treatment
Published: 09/02/2021 13:27 GMT
TCRR
Tcr2 Therapeutics Inc (
TCRR
)
- Tcr² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma.